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Abstract
Background: Population-based studies on endometrial cancer providing survival estimates by age, histology, and
stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial
cancer patients in Germany.
Methods: We used a pooled German national dataset including data from 11 cancer registries covering a
population of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included.
Period analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between
2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age
groups (15-44, 45-54, 55-64, 65-74, and 75+ years).
Results: Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was
observed, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years.
Furthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from
43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for
distant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent
5-year period under investigation.
Conclusion: In this comprehensive population-based survival analysis of patients with endometrial cancer from
Germany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage.
While prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer
patients has been stagnating in the early 21
st century.
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Background
According to estimates by the International Agency for
Research on Cancer (IARC) [1], cancer of the corpus
uteri (commonly called endometrial cancer) ranks as the
2
nd most common gynecological cancer (behind cervical
cancer) worldwide with 287,000 new cases diagnosed in
2008, and ranks as the 3
rd most common cause of gyne-
cologic cancer death (behind cervical and ovarian cancer)
worldwide with 74,000 deaths in 2008. The burden of
endometrial cancer is more severe in developed coun-
tries, including Germany, where endometrial cancer
ranks as the 1
st most common gynecological cancer with
10,776 new cases diagnosed in 2008, and ranks as the 3
rd
most common cause of gynecologic cancer deaths
(behind ovarian and cervical cancer) with 1,760 deaths in
2008 [2].
Endometrial cancer predominantly occurs in postme-
nopausal women [3] and is known to be related to obe-
sity and the reproductive factors parity and age at birth
[4,5]. The worldwide increase in obesity and decrease in
fertility suggest that incidence of endometrial cancer will
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any medium, provided the original work is properly cited.continue to rise [4], indicating that endometrial cancer
will become a substantial public health problem in the
future.
Endometrial cancer is generally associated with a favor-
able prognosis as most patients are diagnosed at early
stages, most likely due to frequent postmenopausal vagi-
nal bleeding, which enables timely diagnosis and com-
mencement of therapy. According to estimates by the
EUROCARE-4 study, age-adjusted 5-year relative survival
(RS) estimates reached 76% in Europe in 1995-1999,
ranging from 68% in Portugal to 84% in Sweden [6].
Nevertheless, patients diagnosed at advanced stage have
poor prognosis [7-9] and survival differs substantially for
histologic types [8,10]. Population-based survival data by
histology have been sparse worldwide, particularly for
Germany as they mostly relied on data from the Saarland
Cancer Registry in the past, covering only 1.3% of the
total German population [11].
In this article we provide detailed (stratified by age, his-
tology, and stage) population-based survival estimates of
endometrial cancer patients in Germany based on a
pooled German national database from 11 population-
based cancer registries, covering 33 million inhabitants.
Furthermore, we employed standard and model-based
period analysis [12-15] to provide most up-to-date esti-
mates and trends of survival in the early 21
st century.
Methods
Database
This analysis is based on a pooled German national data-
set described in detail previously [16]. Briefly, data from 11
population-based German cancer registries (covering a
population of 33 million residents, i.e., 40% of the German
population) with estimated completeness > 90% in the
period 2004-2006 were combined. Patients aged 15 years
or older and diagnosed with malignant tumors during
1997-2006 were included. Follow up with respect to vital
status was performed until the end of 2006.
The current analysis focuses on patients diagnosed with
endometrial cancer (ICD-10 code: C54). According to the
International Classification of Diseases for Oncology
(ICD-O-3) [17] and the Surveillance, Epidemiology and
End Results (SEER) Survival Monograph published in
2007 [8], cancers were grouped into four major histologic
groups: adenocarcinoma, carcinoma not otherwise speci-
fied (NOS), sarcoma and other specified types, and others
(mixture). Adenocarcinomas were further divided into 8
subtypes (adenocarcinoma NOS, papillary, clear cell, squa-
mous metaplasia, mucinous, adenosquamous, endome-
trioid, and other adenocarcinoma). For more details about
histology and morphology codes and their frequencies in
the analyzed dataset please refer to the Appendix.
Stage of disease at diagnosis was defined according to
the recommendation of European Network of Cancer
Registries (ENCR) [18], using a variable indicating
grouped clinical stage with four categories, i.e., localized
(tumors localized/with local spread), regional (tumors
with regional spread), distant (advanced cancer), and
unknown.
Statistical analysis
Period analysis [12,13] was used to derive 5-year relative
survival (RS) estimates for 2002-2006. Period analysis
provides more up-to-date survival estimates than tradi-
tional cohort-based survival analysis by focusing exclu-
sively on survival experience during the most recent
time period for which data are available. This is
achieved by left truncation of observations at the begin-
ning of the period of interest in addition to right censor-
ing of observations at its end. It has been shown by
extensive empirical evaluations that period estimates of
5-year survival for a specific period closely predict 5-
year survival later observed for patients diagnosed in
that period [19,20]. Relative survival was calculated as
the ratio of the observed survival in the group of endo-
metrial cancer patients divided by the expected survival
of a comparable group from general population [21].
Expected survival was derived from life tables for the
population of Germany stratified by age, sex, calendar
period and federal states, using the Ederer II method
[22]. Reporting of relative survival, which has been the
standard method used in population based cancer survi-
val analyses for several decades, was preferred over
reporting of a recently proposed estimate of net survival
[23] for consistency and comparability with other pub-
lished data. Five-year RS was calculated by histologic
subtypes for 3 major age groups (15-49, 50-69, and 70+)
in analogy with the SEER Survival Monograph published
in 2007 [8]. RS estimates were not reported if the stan-
dard errors exceeded 5 percent units. In addition, age-
adjusted 5-year RS was calculated for patient subgroups
defined by histology and stage.
In addition to “standard” period analysis [13], model-
based period analysis [14,15] was employed to assess
recent trends within the 2002-2006 period. Model-based
period analysis can provide survival estimates that are as
up-to date as those from standard period analysis and at
t h es a m et i m em u c hm o r ep r e c i s et h a nt h el a t t e r .I n
addition, this approach allows testing for trends over
time. The method has been described in detail elsewhere
[14]. Briefly, age group-specific numbers of patients at
risk and of deaths by year of follow-up for each single
calendar year between 2002 and 2006 were computed.
The numbers of deaths were then modeled as a function
of age group at diagnosis (entered as categorical variable),
the year of follow-up (categorical variable) and the calen-
dar year (continuous variable) by Poisson regression with
the logarithm of the person-years at risk as offset [14].
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and last year (2006) of the period and a p-value for the
trend in RS between 2002 and 2006 were derived. A p
value of 0.05 was used as the level of significance for
trend tests. Standard errors of the model-based 5-year RS
estimates were calculated using the delta method as pre-
viously described [14].
Age-adjustment for standard period analysis was done
by deriving weighted averages of age-specific 5-year RS
estimates, using weights of five age groups (15-44, 45-
54, 55-64, 65-74, and 75+ years) according to the Inter-
national Cancer Survival Standards [24].
All calculations were performed with the SAS statisti-
cal software package (version 9.2, SAS Institute Inc.,
Cary, North Carolina), using special macros for the per-
iod analysis as described in detail elsewhere [14,25].
Results
The basic characteristics of the dataset used in the current
period analysis for endometrial cancer patients diagnosed
in Germany from 1997 to 2006 are presented in Table 1.
After exclusion of 1,355 patients (4.2%) notified by death
certificate only (DCO) or by autopsy only, and 2 patients
without dates of diagnosis or death, 30,906 cases with a
median age at diagnosis of 67 years were included in the
analysis. 99% of cases were microscopically confirmed.
Although all registries provided staging information, there
were 13,456 cases (44% of total) with complete stage
information.
Age-adjusted and age group-specific 5-year RS estimates
for the time period 2002-2006 by histology are presented in
Table 2. Overall, age-adjusted 5-year RS in 2002-2006 was
81.0%. Prognosis strongly varied by histology, with age-
adjusted 5-year RS ranging from 43.1% (sarcoma) to 94.3%
(squamous metaplasia). Age-adjusted 5-year RS estimates >
80% were observed for endometrioid adenocarcinomas (the
largest group, accounting for 44.2% of all cases), adenocar-
cinoma NOS, squamous metaplasia, and mucinous cancers.
Overall, a moderate age gradient was observed, with 5-year
RS decreasing from 90.0% in age group 15-49 years to
74.8% in age group 70+ years. Patients with uterine sar-
coma had a much stronger age gradient, with 5-year RS
ranging from 75.7% in age group 15-49 years to 31.7% in
age group 70+ years. Furthermore, patients with uterine
sarcoma had the worst prognosis in all age groups. By con-
trast, patients with squamous metaplasia had excellent
prognosis, with 5-year RS estimates > 90%, in all age
groups.
T a b l e3s h o w sa g e - a d j u s t e d5 - y e a rR Sb yh i s t o l o g ya n d
stage. Among the restricted dataset with complete infor-
mation on stage 13,456 cases (44% of total), overall 86%
cases were diagnosed at localized stage and only 7% were
diagnosed at distant stage. Prognosis strongly varied by
stage, with age-adjusted 5-year RS reaching 91.2% for
localized stage, 50.5% for regional stage, and 19.8% for
distant stage. The strong gradient in prognosis by tumor
stage was consistently seen within major histologic sub-
types. A less favorable prognosis and lower proportion in
localized stage were noted for sarcoma.
Model-based age-specific 5-year RS estimates for 2002
and 2006 are shown in Table 4. Overall, there was little
change in prognosis between 2002 and 2006, with age-
adjusted 5-year RS reaching 80.1% in 2002 and 81.3% in
2006. Likewise, similar 5-year RS estimates were observed
for most age subgroups. Only for age group 65-74 years a
significant improvement in prognosis was seen, with 5-
year RS increasing from 78.6% in 2002 to 82.4% in 2006
(change of 3.8 percent units, p = 0.034). In addition, for
both calendar years, a similarly moderate age gradient in
5-year RS was observed.
Table 5 shows model-based age-adjusted 5-year RS esti-
mates in 2002 and 2006 by histology and stage. For the 5-
Table 1 Description of the dataset used in period survival analysis for endometrial cancer patients diagnosed in
Germany, 1997-2006
Registry Population covered
(Million)
Count
(%)
Stage
information available
Median
age
Microscopically Confirmed
(%)
Bavaria 8.13 4,893 (15.8) Yes 67 99.9
Brandenburg 2.55 3,223 (10.4) Yes 66 99.7
Bremen 0.66 882 (2.9) Yes 67 99.6
Hamburg 1.75 1,359 (4.4) Yes 67 98.0
Mecklenburg-Vorpommern 1.69 2,204 (7.1) Yes 66 99.7
Lower Saxony 7.98 4,942 (16.0) Yes 67 97.9
North Rhine-Westphalia 2.62 2,190 (7.1) Yes 67 98.6
Rhineland-Palatinate 0.52 560 (1.8) Yes 68 99.1
Saarland 1.04 1,577 (5.1) Yes 68 99.9
Saxony 4.25 7,096 (23.0) Yes 68 99.6
Schleswig-Holstein 1.85 1,980 (6.4) Yes 68 99.8
Total 33.04 30,906 (100) 13,456 (44%) 67 99.3
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improvement in survival was seen for most subgroups, but
none of these changes was statistically significant. A
reverse trend was even observed for uterine sarcomas.
Discussion
In this manuscript we provide the first comprehensive
population-based analysis of survival of patients with
endometrial cancer from Germany available to date.
Overall, age-adjusted 5-year relative survival in 2002-
2006 was 81.0%. A moderate age gradient was observed,
with 5-year RS decreasing from 90.0% in age group 15-49
years to 74.8% in age group 70+ years. Prognosis further-
more strongly varied by histologic subtypes and stage,
with age-adjusted 5-year RS ranging from 43.1% (for sar-
coma) to 94.3% (for squamous metaplasia), and reaching
Table 2 Age-adjusted and age group-specific 5-year relative survival (RS) for the period 2002-2006 by histologic
subtypes of endometrial cancer patients diagnosed in Germany, 1997-2006
a
Histologic subtypes Overall
b Age groups
15-49 years 50-69 years 70+ years
Count (%
c) RS (SE) Count (%) RS (SE) Count (%) RS (SE) Count (%) RS (SE)
Overall 30,906 (100) 81.0 (0.4) 1,949 (6) 90.0 (1.0) 15,995 (52) 84.8 (0.4) 12,962 (42) 74.8 (0.8)
Adenocarcinoma 28,273 (91.5) 83.9 (0.4) 1,578 (6) 92.6 (1.0) 14,748 (52) 87.6 (0.4) 11,947 (42) 77.8 (0.8)
Adenocarcinoma, NOS 10,427 (33.7) 84.7 (0.7) 606 (6) 93.5 (1.5) 5,353 (51) 88.7 (0.7) 4,468 (43) 78.1 (1.3)
Papillary 1,141 (3.7) 68.4 (2.4) 50 (4) 547 (48) 77.2 (2.7) 544 (48) 57.3 (3.8)
Clear cell 330 (1.1) 62.0 (4.3) 8 (2) 140 (43) 182 (55)
Squamous metaplasia 686 (2.2) 94.3 (2.5) 65 (9) 95.2 (3.9) 375 (55) 92.3 (2.4) 246 (36) 94.1 (4.9)
Mucinous 268 (0.9) 85.2 (4.1) 12 (5) 130 (48) 93.4 (3.9) 126 (47)
Adenosquamous 857 (2.8) 75.0 (2.5) 57 (7) 453 (53) 80.1 (2.9) 347 (40) 64.3 (4.8)
Endometrioid 13,650 (44.2) 86.0 (0.7) 738 (5) 93.7 (1.4) 7,323 (54) 88.8 (0.6) 5,589 (41) 81.3 (1.3)
Other adenocarcinoma
d 914 (2.9) 68.3 (2.5) 42 (4) 427 (47) 70.5 (3.3) 445 (49) 57.2 (4.4)
Carcinoma NOS 619 (2.0) 60.4 (3.3) 42 (7) 272 (44) 69.1 (4.4) 305 (49)
Sarcoma 1,682 (5.4) 43.1 (1.8) 287 (17) 75.7 (3.8) 834 (50) 47.6 (2.4) 561 (33) 31.7 (3.3)
Others (mixture)
e 332 (1.1) 47.3 (4.2) 42 (13) 141 (42) 149 (45)
Abbreviations: NOS = not otherwise specified; RS = point estimates of relative survival (%); SE = standard error (percent units);
a unstable point estimates of RS (SE > 5 percent units) were not reported;
b age-adjusted 5-year relative survival;
c % of histologic subtypes;
d including papillary serous adenocarcinomas (70 cases);
e including other specified carcinomas (42 cases).
Table 3 Age-adjusted 5-year relative survival (RS) for the period 2002-2006 by histologic subtypes and stage for
endometrial cancer patients diagnosed in Germany, 1997-2006
Histologic subtypes Stage
With complete stage information No stage information
Overall Localized Regional Distant
N( %
b) RS (SE) N (%
c) RS (SE) N (%
c) RS (SE) N (%
c) RS (SE) N (%
d) RS (SE)
Overall 13,456 (100) 81.0 (0.4) 11,634 (86) 91.2 (0.7) 814 (6) 50.5 (3.1) 1,008 (7) 19.8 (2.0) 17,450 (56) 79.5 (0.6)
Adenocarcinoma 12,630 (94) 83.9 (0.4) 11,097 (88) 92.2 (0.7) 736 (6) 50.7 (3.3) 797 (6) 20.0 (2.1) 15,643 (55) 83.3 (0.6)
Adenocarcinoma NOS 4,161 (31) 84.7 (0.7) 3,652 (88) 93.7 (1.1) 221 (5) 288 (7) 18.4 (3.3) 6,266 (60) 83.9 (0.9)
Papillary/clear cell 664 (5) 68.0 (2.2) 523 (79) 83.0 (3.0) 61 (9) 14.0 (4.9) 80 (12) 10.4 (5.0) 807 (55) 70.1 (2.7)
Mucinous/Squamous metaplasia 440 (3) 91.1 (2.2) 388 (88) 96.9 (3.2) 28 (6) 24 (5) 514 (54) 90.8 (2.9)
Adenosquamous 443 (3) 75.0 (2.5) 367 (83) 86.1 (3.7) 35 (8) 41 (9) 414 (54) 72.9 (3.7)
Endometrioid 6,499 (48) 86.0 (0.7) 5,841 (90) 92.9 (1.0) 344 (5) 57.2 (4.9) 314 (5) 22.3 (3.5) 7,151 (52) 84.9 (0.9)
Other adenocarcinoma 423 (3) 68.3 (2.5) 326 (77) 76.8 (4.4) 47 (11) 50 (11) 5.6 (4.5) 491 (54) 71.6 (3.4)
Sarcoma 521 (4) 43.1 (1.8) 350 (67) 61.8 (4.4) 48 (9) 123 (24) 13.7 (4.0) 1,161 (69) 40.1 (2.1)
Abbreviations: NOS = not otherwise specified; RS = point estimates of relative survival (%); SE = standard error (percent units);
a unstable point estimates of RS (SE > 5 percent units) were not reported;
b % of histology;
c % of those with complete stage information;
d % of cases without stage information.
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tant stage. For the recent 5-year period under investiga-
tion, a trend towards improvement in survival was seen
for most subgroups assessed, which was though rather
modest and, except for age group 65-74 years, not statis-
tically significant.
We found similar results when data were restricted to
Saarland only. Therefore, the previous estimates of can-
cer survival from Germany, which were often based on
Saarland alone, most likely had been representative.
However, the extended database allowed much more
detailed and precise estimates: For example, due to inclu-
sion of 30,906 cases from multiple registries rather than
1,577 cases from Saarland alone, the standard error for 5-
year relative survival of endometrial cancer overall
decreased from 1.9% to 0.4%. Furthermore, our estimates
of overall 5-year RS of 81.0% for Germany in 2002-2006
are very close to the corresponding estimate of 80.4% for
the USA in 2002-2006 [16], and only slightly higher than
the estimated EUROCARE-4 mean of 78.0% in 2000-
2002 [26].
Our finding of no major improvement in survival for
most subgroups within the 5-year period is consistent
with three large population-based studies [7,15,26] which
likewise showed that survival of endometrial cancer has
been stagnating. For the calendar period 2000-2004, a
trend towards improvement in survival was seen in 12
European countries, but reached statistical significance
only for Estonia [15]. Furthermore, the EUROCARE-4
study using data from 47 European cancer registries [26]
Table 4 Model-based age group-specific 5-year relative survival (RS) in 2002 and 2006 for endometrial cancer patients
diagnosed in Germany,1997-2006
Age 2002 (1) 2006 (2) Change of RS
(2)-(1)
a
P-value
b
Count (%) RS (SE) Count (%) RS (SE)
Age groups
15-44 years 94 (2) 92.8 (2.0) 114 (3) 91.3 (2.4) -1.5 0.691
45-54 years 398 (10) 87.2 (1.5) 412 (11) 88.6 (1.3) 1.4 0.551
55-64 years 1,028 (27) 86.1 (0.9) 887 (23) 85.4 (1.0) -0.7 0.670
65-74 years 1,236 (33) 78.6 (1.2) 1,368 (36) 82.4 (1.0) 3.8 0.034
75+ years 1,047 (28) 72.0 (1.6) 1,028 (27) 71.8 (1.6) -0.2 0.952
Overall
c 3,803 (100) 80.1 (0.7) 3,809 (100) 81.3 (0.6) 1.2 0.256
Abbreviations: RS = point estimates of relative survival (%); SE = standard error (percent units);
a difference in percent units;
b the differences between RS estimates were tested using model-based period analysis;
c age-adjusted.
Table 5 Model-based age-adjusted 5-year relative survival in 2002 and 2006 by histology and stage for endometrial
cancer patients diagnosed in Germany, 1997-2006
Histology Stage
a 2002 (1) 2006 (2) Change of RS
(2)-(1)
P-value
b
Count RS (SE) Count RS (SE)
Adenocarcinoma 3,511 82.6 (0.7) 3,495 84.5 (0.6) 1.9 0.066
Adenocarcinoma, NOS 1,526 84.7 (1.0) 700 84.3 (1.1) -0.3 0.848
Papillary/clear cell
c 322 67.0 (2.7) 186 68.9 (2.6) 1.9 0.643
Mucinous/squamous/
adenosquamous
228 80.5 (3.2) 157 85.2 (2.5) 4.7 0.265
Endometrioid 1,435 85.7 (0.9) 2,452 85.8 (0.9) 0.1 0.961
Sarcoma 199 48.6 (2.6) 223 39.7 (2.6) -8.9 0.048
Others (mixture)
d 93 55.8 (4.1) 91 54.1 (4.1) -1.7 0.789
All Localized 1,409 90.5 (1.0) 1,497 91.8 (0.9) 1.3 0.362
Regional 91 47.0 (4.2) 137 53.3 (4.0) 6.3 0.368
Distant 116 19.4 (2.8) 146 21.4 (2.9) 2.0 0.641
Overall 1,616 82.8 (0.9) 1,780 83.4 (0.9) 0.5 0.721
Abbreviations: NOS = not otherwise specified; RS = point estimate of relative survival (%); SE = standard error (percent units);
a restricted to cases with complete stage information;
b the differences between RS (percent units) were tested using model-based period analysis;
c including other adenocarcinoma;
d including carcinoma NOS.
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the calendar period 1997-2002, though improvements in
survival were seen over the period 1991-1996. A study
based on the SEER data from the USA also found no
improvement in 5-year relative survival for the period
1998-2003 [7]. These trends are in contrast to observa-
tions for earlier periods. A steady increase in 5-year RS
estimates for earlier periods had been reported, for exam-
ple, for the Nordic [27] and other European countries
[28-30], which could be mainly attributed to early diag-
nosis due to introductions of ultrasonography in the
1980s [31] and to advances in techniques of endometrial
biopsy [3].
Given that survival of endometrial cancer is already
rather good overall, with 5-year RS estimates exceeding
80% in 2002-2006 for Germany and the USA [16], and
approaching 80% in 2000-2002 for most European coun-
tries [26], further improvement may be difficult to
achieve and stagnation of survival rates may not be too
surprising. So far, screening (e.g., by transvaginal ultra-
sound) for endometrial cancer in asymptomatic women
at average risk is not recommended due to lack of suffi-
cient evidence [32-35]. Increased rates in high-risk histo-
logic subtypes with poor survival such as uterine
sarcomas [36-38], as suggested by other studies [39], also
contribute to stagnation of further improvement in over-
all survival rates. Poor survival of uterine sarcomas is
likely due to lack of reliable diagnostic test [36,37], and
to limited beneficial effect of adjuvant therapies [36].
Our finding of a statistically significant improvement in
survival only for age group 65-74 years, but not for other
age groups, may reflect enhanced dissemination of effec-
tive therapy to older age groups, but not to the “oldest
old”. A previous analysis of EUROCARE data [40] also
reported that survival in age group 55-69 years improved
more than that in age group 70-84 years. Our observa-
tions of a less favorable prognosis in elderly women and
of a moderate age gradient are consistent with other stu-
dies [8,41,42]. The less favorable prognosis of endome-
trial cancer in the oldest age group might be in part
attributable to comorbidities and less access to therapeu-
tic innovations [6,43], as old patients are generally under-
represented in cancer clinical trials [43]. Nevertheless,
the age gradient in relative survival for patients with
endometrial cancer is less pronounced than the age gra-
dient observed for other types of cancer, and 5-year rela-
tive survival exceeded 70% even in the oldest age group.
We observed a strong variation in survival by histologic
subtypes, consistent with other studies [8,42,44]. The pre-
dominant theory for the etiology of endometrial cancer is
that development and progression of this cancer is
strongly related to high bioavailable estrogens and/or low
progesterone (unopposed estrogen hypothesis) [5,45,46].
The physiological effects of these hormones on the
endometrium are transmitted by estrogen receptors (ER)
and progesterone receptors (PR) [47,48]. Given that the
expressions and distributions of ER (ER-a and ER-b) and
PR (PR-A and PR-B) have been associated with different
survival of endometrial cancer in several studies [49,52], it
is plausible to assume that different profiles of ER/PR
expressions and distributions in histologic subtypes of
endometrial cancer may contribute to the strong variation
in survival by histologic subtypes.
In agreement with previous studies (7-9, 42], we found a
strong gradient in survival by stage. Early detection is the
key for overall good prognosis of endometrial cancer as
most women diagnosed at localized stage can be cured by
surgery alone [53]. Endometrial cancer is usually diag-
nosed at an early stage (86% in our data) due to abnormal
vaginal bleeding. Women (especially after menopause)
experiencing abnormal vaginal bleeding should undergo
diagnostic tests, e.g., endometrial sampling with cytological
examination and measuring endometrial thickness with
transvaginal ultrasound (TVU) [34,54]. Although there is
insufficient evidence to recommend screening for endo-
metrial cancer in asymptomatic women at average risk,
women at very high risk of endometrial cancer should
consider beginning annual testing for early detection at
age 35 years [32,33].
Although information on treatment was too incomplete
to be used in our data, surgery is the cornerstone of ther-
apy for endometrial cancer regardless of stages of the dis-
ease [55]. For patients with advanced stage or with
aggressive histologic subtypes, adjuvant therapy is desir-
able. In addition, centralized care provided by gynecologic
oncologists is also an important prognostic factor for
endometrial cancer, particularly for patients diagnosed at
distant stage as they are more likely to undergo staging
surgery and to receive adjuvant chemotherapy [56,57].
Our study has several strengths and limitations. This is
the first population-based study from Germany providing
survival estimates of endometrial cancer, using a pooled
German national dataset with a large sample size (30,906
cases) and covering a population of 33 million people
(40% of the German population). Furthermore, this study
provided most up-to-date and comprehensive survival
estimates of endometrial cancer in the early 21
st century,
using the techniques of standard and model-based period
analysis. Limitations are mainly related to limited staging
information. Stage information was available for 44% of
cases only, precluding joint stratification by stage and
histology in time trend analyses. Patients with stage
information were on average 2.6 years younger and had
more often adenocarcinoma than carcinoma NOS, sar-
coma or other (mixture) histologies, and had a slightly
higher age-adjusted survival than those without stage
information (81.1 (0.4)) versus 79.5 (0.6). Another limita-
tion concerns lack of treatment information.
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In summary, in this first comprehensive population-
based study from Germany we demonstrate that prog-
nosis of endometrial cancer moderately varied by age,
and strongly varied by histology and stage. In addition,
while prognosis was found to be rather good overall,
further improvement in 5-year relative survival of endo-
metrial cancer patients has been stagnating in the early
21
st century except for age group 65-74 years. Progress in
screening methods for early detection in asymptomatic
women at high risk and dissemination of advances in
therapeutic oncology to the population level, in particular
for patients with biologically aggressive histologic sub-
types (e.g., uterine sarcomas) and older patients, might
be most important for further improvement in survival of
endometrial cancer patients in the 21
st century.
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Table 6 Description of histologic subtypes of endometrial cancer patients diagnosed in Germany, 1997-2006
Classification of
histological subtypes
ICD-O-3 codes Frequency
(N)
Percent
(%)
a. Adenocarcinoma 8050,8140-8147,8160-8162,8180-8221,8250-8506,8520-8550,8560,8570-8573,8940-8941 28,273 91.5
Adenocarcinoma, NOS 8140 10,427 33.7
Papillary 8050,8260 1,141 3.7
Clear cell 8310 330 1.1
With squamous
metaplasia
8570 686 2.2
Mucinous 8480-8481 268 0.9
Adenosquamous 8560 857 2.8
Endometrioid 8380 13,650 44.2
Other adenocarcinoma
a 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8381-8459,8461-8479,8482-
8506,8520-8550,8571-8573,8940-8941,8460
914 2.9
b. Carcinoma NOS 8010-8022 619 2.0
c. Sarcoma and other
specified types
8680-8713,8720-8790,8800-8920,8930-8933,8950-8982,8990-8991,9000-9030,9040-9055,9060-
9110,9120-9134,9141-9340,9350-9364,9380-9512,9530-9581
1,682 5.4
d. Others (mixture)
b, c 8000-8004,8051-8130,8921,8935, 8030-8045,8150-8155,8170-8171,8230-8248,8510-8512,8561-
8562,8580-8671
322 1.1
In total 8000-9581 30,906 100
Abbreviation: NOS = not otherwise specified;
a including papillary serous adenocarcinoma (70 cases);
b including other specified carcinomas (42 cases);
c Missing histologies coded as 8000 were included in this subgroup.
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